Your browser doesn't support javascript.
loading
Cerebellum/liver index on baseline 18F-FDG PET/CT to improve prognostication in post-transplant lymphoproliferative disorders: a multicenter retrospective study.
Morland, David; Kanagaratnam, Lukshe; Hubelé, Fabrice; Toussaint, Elise; Choquet, Sylvain; Kas, Aurélie; Caquot, Pierre-Ambroise; Haioun, Corinne; Itti, Emmanuel; Leprêtre, Stéphane; Decazes, Pierre; Bijou, Fontanet; Schwartz, Paul; Jacquet, Caroline; Chauchet, Adrien; Matuszak, Julien; Kamar, Nassim; Payoux, Pierre; Durot, Eric.
Afiliación
  • Morland D; Médecine Nucléaire, Institut Godinot, Reims, France. david.morland@reims.unicancer.fr.
  • Kanagaratnam L; Laboratoire de Biophysique, UFR de Médecine, Université de Reims Champagne-Ardenne, Reims, France. david.morland@reims.unicancer.fr.
  • Hubelé F; CReSTIC, EA 3804, Université de Reims Champagne-Ardenne, Reims, France. david.morland@reims.unicancer.fr.
  • Toussaint E; Unità di Medicina Nucleare, TracerGLab, Dipartimento di Radiologia, Radioterapia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy. david.morland@reims.unicancer.fr.
  • Choquet S; Unité d'Aide Méthodologique, Pôle Recherche et Santé Publique, CHU de Reims, Reims, France.
  • Kas A; Médecine Nucléaire, CHU de Strasbourg, ICANS, Strasbourg, France.
  • Caquot PA; Hématologie, CHU de Strasbourg, ICANS, Strasbourg, France.
  • Haioun C; Hématologie, CHU Pitié-Salpêtrière Charles Foix, Sorbonne Université, AP-HP, Paris, France.
  • Itti E; Médecine Nucléaire, CHU Pitié-Salpêtrière Charles Foix, Sorbonne Université, AP-HP, Paris, France.
  • Leprêtre S; Médecine Nucléaire, Institut Godinot, Reims, France.
  • Decazes P; Médecine Nucléaire, CHU Pitié-Salpêtrière Charles Foix, Sorbonne Université, AP-HP, Paris, France.
  • Bijou F; Hématologie, CHU Henri Mondor, AP-HP, Créteil, France.
  • Schwartz P; Médecine Nucléaire, CHU Henri Mondor, AP-HP, Créteil, France.
  • Jacquet C; Inserm U1245 et Département d'Hématologie, Centre Henri Becquerel et Normandie Univ, UNIROUEN, Rouen, France.
  • Chauchet A; Médecine Nucléaire, Centre Henri Becquerel, Rouen, France.
  • Matuszak J; Hématologie, Institut Bergonié, Bordeaux, France.
  • Kamar N; Médecine Nucléaire, Institut Bergonié, Bordeaux, France.
  • Payoux P; Hématologie, CHU de Nancy, Nancy, France.
  • Durot E; Médecine Nucléaire, CHU de Besançon, Besançon, France.
EJNMMI Res ; 14(1): 49, 2024 May 27.
Article en En | MEDLINE | ID: mdl-38801646
ABSTRACT

BACKGROUND:

Besides International Prognostic Index (IPI) score, baseline prognostic factors of post-transplant lymphoproliferative disorders (PTLD) are poorly identified due to the rarity of the disease. New indexes derived from healthy organ uptake in baseline 18F-FDG PET/CT have been studied in immunocompetent lymphoma patients. The aim of this study is to evaluate the performances of the cerebellum-to-liver uptake ratio (denoted as CLIP) as a prognostic factor for PFS and OS. This retrospective multicenter study is based on patients with PTLD included in the K-VIROGREF cohort. The previously published threshold of 3.24 was used for CLIP in these analyses.

RESULTS:

A total of 97 patients was included with a majority of monomorphic diffuse large B-cell lymphoma subtype (78.3%). Both IPI score (≥ 3) and CLIP (< 3.24) were significant risk factors of PFS with corresponding hazard ratios of 2.0 (1.0-4.0) and 2.4 (1.3-4.5) respectively. For OS, CLIP was not significant and resulted in a hazard ratio of 2.6 (p = 0.059). Neither IPI score or Total Metabolic Tumor Volume reached significance for OS.

CONCLUSION:

CLIP is a promising predictor of PFS and perhaps OS in PTLD. Further prospective studies are needed to confirm these results.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: EJNMMI Res Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: EJNMMI Res Año: 2024 Tipo del documento: Article País de afiliación: Francia